AAC Accepts, published online ahead of print on 6 April 2009

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Huggins, J. Articles by Hruby, D. Search for Related Content PubMed PubMed Citation Articles by Huggins, J. Articles by Hruby, D.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother. doi:10.1128/AAC.00021-09
Copyright (c) 2009, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Non-human primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246

John Huggins, Arthur Goff, Lisa Hensley, Eric Mucker, Josh Shamblin, Carly Wlazlowski, Wendy Johnson, Jennifer Chapman, Tom Larsen, Nancy Twenhafel, Kevin Karem, Inger K. Damon, Chelsea M. Byrd, Tove’ C. Bolken, Robert Jordan, and Dennis Hruby^*

US Army Medical Research Institute of Infectious Diseases, Frederick, MD; Centers for Disease Control and Prevention, Atlanta, GA; SIGA Technologies, Corvallis, OR

^* To whom correspondence should be addressed. Email: dhruby{at}siga.com.

ST-246, a potent orthopoxvirus egress inhibitor, is safe and effective at preventing disease and death in small animal models challenged by several different pathogenic poxviruses. In this report, the antiviral efficacy of ST-246 was assessed in non-human primates infected with variola virus or monkeypox virus. The data indicates that once per day oral dosing with ST-246 protects animals from poxvirus disease as measured by reduction in viral load, appearance of lesions and survival.